Gene Saragnese
Prior to joining the Mirada Medical board as Chairman, Gene Saragnese served as the Philips Healthcare CEO of Philips Imaging Systems from April 2009 until May 2015. Before joining Philips, Mr. Saragnese served as GE Healthcare’s Vice President and General Manager of Molecular Imaging and Computed Tomography. Prior to that, he served as Chief Technology Officer for GE Healthcare. In this role, Mr. Saragnese led Global Product Development Engineering and Component Operations around the world, including Corporate Research sites in New York, China, India and Germany. He has also served as General Manager for GE Medical Systems’ Global MRI business and the leader for GE Medical Systems’ Global MRI Engineering organization. Prior to his career in healthcare, Mr. Saragnese held management roles with GE, RCA, Martin Marietta and Lockheed Martin in the aerospace industry. He is a graduate of Rutgers College of Engineering in New Jersey
Hugh Bettesworth
Hugh Bettesworth has worked in the software industry for over fifteen years, the last twelve in the clinical sector. He joined Mirada in 2001, and took over the development of the company’s image fusion product lines in 2003. Following Mirada’s acquisition by first CTI Molecular Imaging and then Siemens Molecular Imaging, Hugh continued to develop the market for these products, focusing on the delivery of specialist molecular imaging workflows into new markets and in particular the PACS market. He led a management buyout in 2008 which re-established Mirada’s independent status and provided the platform for the innovative software developments that have resulted in Mirada’s subsequent growth and leading technical position today.
Prof. Sir Michael Brady
Prof. Sir Michael Brady FRS, FREng, FMedSci is now Professor of Oncological Imaging in the Department of Oncology at the University of Oxford, having retired in 2010 as Professor of Information Engineering. He is co-Director of the Oxford Cancer Imaging Centre. He combines his work in oncology with a range of entrepreneurial activities. He is Deputy Chairman of Oxford Instruments plc. and also a founding director of successful startup companies such as Guidance and, of course, Mirada Medical. He was elected an Honorary Fellow of the IET and Institute of Physics. He was awarded the IEE Faraday Medal in 2000 and also the IEEE Third Millennium Medal for the UK. In 2005 the Royal Institution awarded Professor Sir Michael Brady the Henry Dale Prize for “outstanding work on a biological topic by means of an original multidisciplinary approach”.
Mark Evans
Mark Evans FCA, MCT, MBA is a Chartered Accountant (UK equivalent to a CPA), a qualified Corporate Treasurer and holds an MBA from THE Saïd Business School, Oxford University. Mark’s experience runs from technology start-ups to being a CFO responsible for a EUR 800m business within a multi-national corporation. Mark’s experience in medical technology includes being European Finance Director for CTI Molecular Imaging; COO then MD of Mirada Solutions Ltd.; MD of PETNET Solutions in the UK, a radiopharmaceutical production company; and Vice President and European CFO of a 26 market region of Siemens Diagnostics.
David Gudgin
David Gudgin qualified as a management accountant with ICL before spending 3 years at the BBC. In 1999 he joined 3i as an investor in European technology based in London and Amsterdam. In 2002 he moved to Foursome Investments (now Frog Capital) as the lead investor of two funds, an environmental technology fund and a later stage development capital fund. David joined Close Ventures in 2005 and became a partner in Albion Ventures in 2009. David has a BSc in Economics from Warwick University.
